Bio-Techne: Q2 Earnings Insights

Shares of Bio-Techne TECH remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share increased 50.00% year over year to $1.62, which beat the estimate of $1.37.

Revenue of $224,253,000 higher by 21.26% year over year, which beat the estimate of $206,500,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Bio-Techne hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Feb 02, 2021

Time: 09:00 AM

ET Webcast URL: http://public.viavid.com/player/index.php?id=143031

Technicals

Company's 52-week high was at $361.47

Company's 52-week low was at $155.17

Price action over last quarter: Up 12.43%

Company Description

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells a variety of antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers, and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.